查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1618746

下一代乳癌診斷和篩檢市場：按產品、診斷技術、篩檢技術、應用和最終用戶 - 2025-2030 年全球預測

Next-Generation Breast Cancer Diagnostic & Screening Market by Product, Diagnostic Technology, Screening Technology, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

下一代乳癌診斷與篩檢市場2023年估值為228.1億美元，預計到2024年將達到251.2億美元，複合年成長率為10.91%，到2030年將達到471.1億美元，預計將達到1000萬美元。

下一代乳癌診斷和篩檢市場包括基因組學、蛋白質組學和液態切片等先進技術和方法，旨在改善乳癌的早期檢測、診斷和監測。這些創新的需求源於乳癌發病率的增加、對無創技術的需求以及個人化照護的需求。應用範圍廣泛，包括用於癌症風險評估的基因檢測、使用基於人工智慧的影像診斷系統進行早期檢測以及治療效果的即時監測。最終用戶主要是醫院、診斷實驗室、研究機構和個人化醫療公司。根據市場洞察，成長的推動因素包括醫療保健意識的提高、技術進步、政府支持的增加以及向基於價值的護理的轉變。擴大人工智慧和機器學習的整合、提供預測分析以及開發可攜式、經濟高效的診斷工具以覆蓋服務不足的人群，存在機會。公司可以透過與高科技公司合作並投資研發來利用這些機會。然而，某些限制因素阻礙了成長，包括高成本、嚴格的法律規範以及低收入地區的准入有限。也存在資料隱私問題和對高技能專業人員的需求等挑戰。多組體學資料的無縫整合、開發負擔得起的診斷試劑套件和即時人工智慧分析等領域的創新提供了有希望的成長路徑。此外，我們專注於以患者為中心的護理創新，例如家庭診斷解決方案，可以提高我們的競爭力。市場是動態的，其特點是技術快速採用和競爭激烈，從而促進持續創新並需要強力的適應策略。成功的關鍵往往在於協作研究、策略夥伴關係以及對監管變化的回應。為公司提供的策略建議包括投資於客戶教育和參與、透過透明度建立信任以及優先考慮跨學科合作，以促進理解和對抗乳癌的整體方法。

主要市場統計
基準年[2023] 228.1億美元
預計年份 [2024] 251.2億美元
預測年份 [2030] 471.1億美元
複合年成長率（%） 10.91%

市場動態：快速發展的下一代乳癌診斷和篩檢市場的關鍵市場洞察

供需的動態交互作用正在改變下一代乳癌診斷和篩檢市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球乳癌發生率上升
    • 對疾病早期診斷和治療的興趣日益濃厚
    • 政府努力提高人們對乳癌的認知
  • 市場限制因素
    • 昂貴的乳癌診斷和篩檢技術
  • 市場機會
    • 下一代乳癌診斷和篩檢技術的進展
    • 策略聯盟和投資以生產創新的乳癌診斷解決方案
  • 市場挑戰
    • 製造複雜性和嚴格的監管核准流程

波特五力：引領下一代乳癌診斷與篩檢市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對下一代乳癌診斷和篩檢市場的影響

外部宏觀環境因素在塑造下一代乳癌診斷和篩檢市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解下一代乳癌診斷和篩檢市場的競爭格局

對下一代乳癌診斷和篩檢市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣下一代乳癌診斷和篩檢供應商的市場績效評估

FPNV 定位矩陣是評估下一代乳癌診斷和篩檢市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，為下一代乳癌診斷和篩檢市場制定成功之路

對於旨在加強其在全球市場的影響力的公司來說，對下一代乳癌診斷和篩檢市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球乳癌發生率正在上升
      • 疾病早期診斷和治療的趨勢日益明顯
      • 政府採取措施提高人們對乳癌的認知
    • 抑制因素
      • 昂貴的乳癌診斷和篩檢技術
    • 機會
      • 下一代乳癌診斷和篩檢技術的進展
      • 策略聯盟和投資以生產創新的乳癌診斷解決方案
    • 任務
      • 製造複雜性和嚴格的監管核准流程
  • 市場區隔分析
    • 產品：需要先進的乳房攝影系統來改善臨床結果
    • 最終用戶：擴大乳癌診斷在醫院的使用，為更廣泛的患者群體提供服務
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章下一代乳癌診斷與篩檢市場：依產品

  • 配件
  • 乳房攝影系統
  • 軟體和服務

第7章下一代乳癌診斷/篩檢市場診斷技術

  • DNA微陣列
  • 實驗室晶片和逆轉錄 PCR
  • 分子診斷
  • 次世代定序
  • 蛋白質微陣列
  • qPCR 和多重檢測

第8章下一代乳癌診斷與篩檢市場篩檢技術

  • 電離乳房攝影技術
    • 3D 乳房斷層合成
    • 模擬乳房X光攝影
    • 錐狀射束電腦斷層掃描 (CBCT)
    • 造影乳房X光攝影（CEM）
    • 全視野數位乳房攝影（FFDM）
    • 分子乳房成像/乳房特異性伽瑪成像 (MBI/BSGI)
    • 正電子發射乳房X光攝影（PEM）
    • 正子斷層掃描與電腦斷層掃描 (PET-CT)
  • 非電離乳房攝影技術
    • 自動全乳超音波(AWBU)
    • 乳腺核磁共振檢查
    • 乳房熱成像
    • 乳腺超音波檢查
    • 電電阻掃描
    • 光學成像

第9章下一代乳癌診斷和篩檢市場：按應用分類

  • 癌症篩檢
  • 伴同性診斷
  • 風險分析
  • 治療監測

第10章下一代乳癌診斷與篩檢市場：依最終用戶分類

  • 乳腺癌護理中心
  • 影像診斷中心
  • 醫院/診所

第11章北美和南美下一代乳癌診斷和篩檢市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區下一代乳癌診斷與篩檢市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的下一代乳癌診斷和篩檢市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • GE Healthcare 發布 MyBreastAI 套件，幫助臨床醫師加速乳癌檢測
    • Exact Sciences 透過富有遠見的合作推動創新的癌症技術和方法
    • 賽默飛世爾科技 (Thermo Fisher Scientific) 與輝瑞 (Pfizer) 合作，擴大國際市場上針對癌症患者的次世代定序檢測的區域覆蓋範圍
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • Agendia Inc.
  • Agilent Technologies, Inc.
  • ARTIVION INC.
  • Becton, Dickinson and Company
  • Benitec Biopharma Ltd
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • Centogene NV
  • Danaher Corporation
  • Epic Sciences, Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE HealthCare Technologies, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Invivoscribe, Inc.
  • Koninklijke Philips NV
  • Laboratory Corporation of America Holdings
  • Merck & Co., Inc.
  • Myriad Genetics, Inc.
  • Novartis AG
  • Pfizer Inc.
  • QIAGEN NV
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-5C6F41F5AFF0

The Next-Generation Breast Cancer Diagnostic & Screening Market was valued at USD 22.81 billion in 2023, expected to reach USD 25.12 billion in 2024, and is projected to grow at a CAGR of 10.91%, to USD 47.11 billion by 2030.

The scope of the next-generation breast cancer diagnostic and screening market encompasses advanced technologies and methodologies aimed at improving early detection, diagnosis, and monitoring of breast cancer, like genomics, proteomics, and liquid biopsy. Necessity for these innovations stems from increasing breast cancer incidence, demand for non-invasive methods, and the need for personalized care. Applications are broad, including genetic tests for assessing cancer risk, early-stage detection using AI-enhanced imaging systems, and real-time monitoring of treatment efficacy. End-users primarily include hospitals, diagnostic laboratories, research institutes, and personalized medicine companies. Market insights reveal growth driven by rising healthcare awareness, technological advancements, increased governmental support, and a shift towards value-based care. Opportunities are evident in expanding AI and machine learning integrations, offering predictive analytics, and developing portable, cost-effective diagnostic tools to reach underserved populations. For businesses, partnership with tech firms and investing in R&D can capitalize on these opportunities. However, certain limitations impede growth, including high costs, stringent regulatory frameworks, and limited access in low-income regions. Challenges also include data privacy concerns and the need for highly skilled professionals. Innovating in areas such as seamless integration of multi-omics data, developing affordable diagnostic kits, and real-time AI analytics represents promising avenues for growth. Moreover, focus on patient-centered care innovations, such as home-based diagnostic solutions, can provide a competitive edge. The market is dynamic, characterized by rapid technology adoption and high competition, which fosters continuous innovation and necessitates robust adaptive strategies. Success often hinges on collaborations, strategic partnerships, and aligning with regulatory changes. Strategic recommendations for businesses involve investing in customer education and engagement, establishing trust through transparency, and prioritizing cross-disciplinary collaborations to foster a holistic approach to understanding and combating breast cancer.

KEY MARKET STATISTICS
Base Year [2023] USD 22.81 billion
Estimated Year [2024] USD 25.12 billion
Forecast Year [2030] USD 47.11 billion
CAGR (%) 10.91%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Next-Generation Breast Cancer Diagnostic & Screening Market

The Next-Generation Breast Cancer Diagnostic & Screening Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of breast cancer worldwide
    • Growing inclination towards early diagnosis and treatment of diseases
    • Government initiatives to raise awareness regarding breast cancer
  • Market Restraints
    • Expensive breast cancer diagnostic & screening technologies
  • Market Opportunities
    • Advancements in next-generation breast cancer diagnostic & screening technologies
    • Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
  • Market Challenges
    • Complexity in manufacturing and stringent regulatory approval process

Porter's Five Forces: A Strategic Tool for Navigating the Next-Generation Breast Cancer Diagnostic & Screening Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Next-Generation Breast Cancer Diagnostic & Screening Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Next-Generation Breast Cancer Diagnostic & Screening Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Next-Generation Breast Cancer Diagnostic & Screening Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Next-Generation Breast Cancer Diagnostic & Screening Market

A detailed market share analysis in the Next-Generation Breast Cancer Diagnostic & Screening Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Next-Generation Breast Cancer Diagnostic & Screening Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Next-Generation Breast Cancer Diagnostic & Screening Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Next-Generation Breast Cancer Diagnostic & Screening Market

A strategic analysis of the Next-Generation Breast Cancer Diagnostic & Screening Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Next-Generation Breast Cancer Diagnostic & Screening Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agendia Inc., Agilent Technologies, Inc., ARTIVION INC., Becton, Dickinson and Company, Benitec Biopharma Ltd, BGI Genomics Co., Ltd., Bio-Rad Laboratories, Inc., Centogene N.V., Danaher Corporation, Epic Sciences, Inc., Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., Fujifilm Holdings Corporation, GE HealthCare Technologies, Inc., Hologic, Inc., Illumina, Inc., Invivoscribe, Inc., Koninklijke Philips N.V., Laboratory Corporation of America Holdings, Merck & Co., Inc., Myriad Genetics, Inc., Novartis AG, Pfizer Inc., QIAGEN N.V., Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Next-Generation Breast Cancer Diagnostic & Screening Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Accessories, Breast Imaging Systems, and Software & Services.
  • Based on Diagnostic Technology, market is studied across DNA Microarrays, Lab-on-a-Chip & Reverse Transcriptase-PCR, Molecular Diagnostics, Next Generation Sequencing, Protein Microarrays, and qPCR & Multiplexing.
  • Based on Screening Technology, market is studied across Ionizing Breast Imaging Technologies and Non-ionizing Breast Imaging Technologies. The Ionizing Breast Imaging Technologies is further studied across 3D Breast Tomosynthesis, Analog Mammography, Cone-Beam Computed Tomography (CBCT), Contrast-Enhanced Mammography (CEM), Full-Field Digital Mammography (FFDM), Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI), Positron Emission Mammography (PEM), and Positron Emission Tomography and Computed Tomography (PET-CT). The Non-ionizing Breast Imaging Technologies is further studied across Automated Whole-Breast Ultrasound (AWBU), Breast MRI, Breast Thermography, Breast Ultrasound, Electric Impedance Tomography, and Optical Imaging.
  • Based on Application, market is studied across Cancer Screening, Companion Diagnostics, Risk Analysis, and Therapeutic Monitoring.
  • Based on End User, market is studied across Breast Care Centers, Diagnostic Imaging Centers, and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of breast cancer worldwide
      • 5.1.1.2. Growing inclination towards early diagnosis and treatment of diseases
      • 5.1.1.3. Government initiatives to raise awareness regarding breast cancer
    • 5.1.2. Restraints
      • 5.1.2.1. Expensive breast cancer diagnostic & screening technologies
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in next-generation breast cancer diagnostic & screening technologies
      • 5.1.3.2. Strategic alliances and investments to manufacture innovative breast cancer diagnostic solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexity in manufacturing and stringent regulatory approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Need for advanced breast imaging systems for enhanced clinical outcomes
    • 5.2.2. End User: Expanding use of breast cancer diagnostics in hospitals to cater to a wider patient population
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Next-Generation Breast Cancer Diagnostic & Screening Market, by Product

  • 6.1. Introduction
  • 6.2. Accessories
  • 6.3. Breast Imaging Systems
  • 6.4. Software & Services

7. Next-Generation Breast Cancer Diagnostic & Screening Market, by Diagnostic Technology

  • 7.1. Introduction
  • 7.2. DNA Microarrays
  • 7.3. Lab-on-a-Chip & Reverse Transcriptase-PCR
  • 7.4. Molecular Diagnostics
  • 7.5. Next Generation Sequencing
  • 7.6. Protein Microarrays
  • 7.7. qPCR & Multiplexing

8. Next-Generation Breast Cancer Diagnostic & Screening Market, by Screening Technology

  • 8.1. Introduction
  • 8.2. Ionizing Breast Imaging Technologies
    • 8.2.1. 3D Breast Tomosynthesis
    • 8.2.2. Analog Mammography
    • 8.2.3. Cone-Beam Computed Tomography (CBCT)
    • 8.2.4. Contrast-Enhanced Mammography (CEM)
    • 8.2.5. Full-Field Digital Mammography (FFDM)
    • 8.2.6. Molecular Breast Imaging/Breast Specific Gamma Imaging (MBI/BSGI)
    • 8.2.7. Positron Emission Mammography (PEM)
    • 8.2.8. Positron Emission Tomography and Computed Tomography (PET-CT)
  • 8.3. Non-ionizing Breast Imaging Technologies
    • 8.3.1. Automated Whole-Breast Ultrasound (AWBU)
    • 8.3.2. Breast MRI
    • 8.3.3. Breast Thermography
    • 8.3.4. Breast Ultrasound
    • 8.3.5. Electric Impedance Tomography
    • 8.3.6. Optical Imaging

9. Next-Generation Breast Cancer Diagnostic & Screening Market, by Application

  • 9.1. Introduction
  • 9.2. Cancer Screening
  • 9.3. Companion Diagnostics
  • 9.4. Risk Analysis
  • 9.5. Therapeutic Monitoring

10. Next-Generation Breast Cancer Diagnostic & Screening Market, by End User

  • 10.1. Introduction
  • 10.2. Breast Care Centers
  • 10.3. Diagnostic Imaging Centers
  • 10.4. Hospitals & Clinics

11. Americas Next-Generation Breast Cancer Diagnostic & Screening Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Next-Generation Breast Cancer Diagnostic & Screening Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Next-Generation Breast Cancer Diagnostic & Screening Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. GE HealthCare Releases MyBreastAI Suite to Support Clinicians in Accelerating Breast Cancer Detection
    • 14.3.2. Exact Sciences Advances Innovative Cancer Technologies and Approaches Through Visionary Collaborations
    • 14.3.3. Thermo Fisher Scientific & Pfizer Partner to Expand Localized Access to Next Generation Sequencing-Based Testing for Cancer Patients in International Markets
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Agendia Inc.
  • 3. Agilent Technologies, Inc.
  • 4. ARTIVION INC.
  • 5. Becton, Dickinson and Company
  • 6. Benitec Biopharma Ltd
  • 7. BGI Genomics Co., Ltd.
  • 8. Bio-Rad Laboratories, Inc.
  • 9. Centogene N.V.
  • 10. Danaher Corporation
  • 11. Epic Sciences, Inc.
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. Fujifilm Holdings Corporation
  • 15. GE HealthCare Technologies, Inc.
  • 16. Hologic, Inc.
  • 17. Illumina, Inc.
  • 18. Invivoscribe, Inc.
  • 19. Koninklijke Philips N.V.
  • 20. Laboratory Corporation of America Holdings
  • 21. Merck & Co., Inc.
  • 22. Myriad Genetics, Inc.
  • 23. Novartis AG
  • 24. Pfizer Inc.
  • 25. QIAGEN N.V.
  • 26. Siemens Healthineers AG
  • 27. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET RESEARCH PROCESS
  • FIGURE 2. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ACCESSORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST IMAGING SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DNA MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY LAB-ON-A-CHIP & REVERSE TRANSCRIPTASE-PCR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PROTEIN MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY QPCR & MULTIPLEXING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY 3D BREAST TOMOSYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ANALOG MAMMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CONE-BEAM COMPUTED TOMOGRAPHY (CBCT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CONTRAST-ENHANCED MAMMOGRAPHY (CEM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY FULL-FIELD DIGITAL MAMMOGRAPHY (FFDM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY MOLECULAR BREAST IMAGING/BREAST SPECIFIC GAMMA IMAGING (MBI/BSGI), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY POSITRON EMISSION MAMMOGRAPHY (PEM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY (PET-CT), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY AUTOMATED WHOLE-BREAST ULTRASOUND (AWBU), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST MRI, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST THERMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY ELECTRIC IMPEDANCE TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY OPTICAL IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY CANCER SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY RISK ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY THERAPEUTIC MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY BREAST CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC IMAGING CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 77. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 86. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 102. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. AUSTRALIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 108. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 109. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 110. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. CHINA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 114. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 116. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 117. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. INDIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 121. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 122. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 123. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 124. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. INDONESIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 128. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 129. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 130. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 131. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. JAPAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 136. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 137. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 138. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. MALAYSIA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 142. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 144. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 145. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. PHILIPPINES NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 150. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 151. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 152. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. SINGAPORE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 157. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 158. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 159. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. SOUTH KOREA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 163. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 165. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 166. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. TAIWAN NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 172. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 173. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. THAILAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 177. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 178. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 179. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 180. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. VIETNAM NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 193. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 194. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 195. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 196. DENMARK NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 199. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 200. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 201. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 202. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 203. EGYPT NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 207. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 208. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 209. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 210. FINLAND NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 213. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 214. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 215. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 216. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. FRANCE NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 222. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 223. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 224. GERMANY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 227. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 229. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 230. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. ISRAEL NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 235. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 236. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY NON-IONIZING BREAST IMAGING TECHNOLOGIES, 2018-2030 (USD MILLION)
  • TABLE 237. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 238. ITALY NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY DIAGNOSTIC TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. NETHERLANDS NEXT-GENERATION BREAST CANCER DIAGNOSTIC & SCREENING MARKET SIZE, BY SCREENING TECHNOLOGY, 20